RESEARCH ARTICLE

Ocular Manifestations in Patients with Coronavirus Disease 2019 (COVID-19): A Real World Multicenter Observational Study in Egypt

Raouf Gaber1, Sherief Abd-Elsalam2*, Mai Khalaf3, Eslam Saber Esmail2, Ossama Ashraf Ahmed1, Hatem Fawzy1, Shaimaa Soliman3, Kamal Okasha6, Doaa El Amrousy7 and Ahmed M. Ghoneim1

1 Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt
2 Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt
3 Internal Medicine, Faculty of Medicine, Ain-Shams University, Cairo, Egypt
4 Department of Ophthalmology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt
5 Public Health and Community Medicine, Menoufia University, Menoufia, Egypt
6 Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt
7 Department of Pediatric, Faculty of Medicine, Tanta University, Tanta, Egypt

Abstract:
Background: The aim of the work was to evaluate the ocular manifestations in the patients with COVID-19 and its role in the prediction of the course and the outcome of the disease.

Methods: This retrospective study was conducted at two tertiary referral COVID-19 isolation hospitals in two major university hospitals in Egypt. Two hundred and twenty-eight patients were enrolled in the study. The medical records of patients who had clinically confirmed COVID-19 between 1/5/2020 to 15/7/2020 were retrospectively reviewed. Data were collected from patient charts, including age, sex, accommodation, ocular manifestations, fever, headache, cough, dyspnea, anosmia, cyanosis, abdominal pain, anorexia, liver, kidney, cardiac manifestations, CT, X-ray finding, blood tests, and outcome of the disease.

Results: Thirty-four patients with ocular manifestation were finally enrolled in the study with a mean age of 42.1 years; 20 patients (58.8%) were men. The incidence of ocular manifestation was 14.9% (34/228). All patients with ocular manifestations had conjunctivitis (redness, epiphora, foreign body sensation), which had been treated and resolved completely within 10 days in all patients without any permanent ocular damage. There was a trend between the presence of ocular manifestations and the associated milder disease course, although this trend was not statistically significant.

Conclusion: Ophthalmic manifestation is common in patients with COVID-19 and it occurs more frequently in patients with mild to moderate form of COVID-19, but it could not predict the patient’s mortality.

Keywords: Conjunctivitis, Eye, Pandemic, SARS, SARS-CoV-2, Viruses.

1. INTRODUCTION

Coronavirus disease 2019 (COVID-19) has been reported to start in Chinese patients. Currently, the disease is spreading rapidly around the world. The pathogen for COVID-19 is a new coronavirus (SARS-CoV-2 Coronavirus), which has been identified as a member of the Coronaviridae family. Another member of this family called SARS-CoV-1 was responsible for severe acute respiratory syndrome. When compared to SARS-CoV-1, SARS-CoV-2 has a similar binding receptor, similar systemic features, and epidemiological specific characteristics [1 - 11].

Although up till now, it is not evinced that infection with
SARS-CoV-1 was associated with conjunctivitis, some reports have confirmed the eye as a possible site of virus transmission [12].

There are few reports in the medical literature that identify the ocular manifestation of SARS-CoV-2 [13]. Moreover, researchers have not reported the significance of these ocular finding in predicting the course of the disease. So, the aim of this study was to evaluate the ophthalmological involvement in patients confirmed to have COVID-19 and its rule in the prediction of the course of the disease.

2. METHODS

This retrospective study was carried out at isolation hospitals in the faculty of medicine, Tanta University and Ain-shams University, Egypt. It was conducted according to the principles of the Helsinki Declaration and was approved by the ethical review board of both faculties. Personal data of the participants were kept confidential and used only for research purposes. Results and images were collected from the patients after their consent. Consent was taken from the patient to post the image included in the manuscript.

The medical records of patients who had been laboratory confirmed to be positive for COVID-19 between 1/5/2020 to 15/7/2020 were reviewed. The collected data included sociodemographic data such as age, sex, and residence. Medical, laboratory, and radiological data were also reviewed for the presence of fever, headache, cough, dyspnea, anosmia, cyanosis, abdominal pain, anorexia, hepatic, renal, or cardiac manifestations. Computerized tomography (CT) and X-ray chest findings were also recorded. Blood tests results, including red blood cells, white blood cells, platelets, hemoglobin concentration, the international normalized ratio (INR), D dimer, and the outcome of the disease were also collected.

Ocular manifestations for any ocular symptoms or any signs suggestive of viral infection like conjunctival hyperemia, epiphora, lid edema, irritation, or foreign body sensation were also recorded.

The severity of COVID-19 disease was clinically evaluated and mild stage was characterized by the absence of pneumonia and hypoxia. Meanwhile, moderate stage was characterized by the presence of pneumonia in the absence of the criteria of the severe stage. The severe form of the disease was characterized by the presence of any of the following: oxygen saturation less than 90%, involvement of more than 50% of lung field, a respiratory rate more than 30 cycles per minute, or any of the manifestations of respiratory distress.

2.1. Statistical Analysis

The collected data were tested for normality by Shapiro Wilks test. Normally distributed quantitative data were expressed in the form of mean and Standard Deviation (SD), while skewed quantitative data were expressed in the form of median and range. Categorical data were expressed in the form of number (No.) and percentage (%). Student’s t-test was used for comparison of normally distributed quantitative variables, while Mann Whitney’s test was used for comparison of abnormally distributed ones. Chi-square test (x2) was used for comparison of categorical variables and whenever any of the expected cells were less than five, Fischer’s Exact test was used. Logistic regression was used to ascertain the effect of the possible risk factors on the mortality of the included patients. Two-sided P- value of < 0.05 was considered statistically significant. All the analyses were performed using SPSS statistical package version 23 (SPSS Inc. Released 2015. IBM SPSS statistics for windows, version 23.0, Armnok, NY: IBM Corp).

3. RESULTS

Two hundred and twenty eight charts (228) of COVID-19 patients were included in this study. Among them, 34 patients (14.9%, 95% CI: 10.1-19.7%) showed ocular manifestations. The ocular manifestation that was present in all the affected patients was conjunctivitis manifested by conjunctival hyperemia, epiphora, lid edema, and foreign body sensation (Fig. 1).

![Fig (1). Conjunctivitis, manifested by conjunctival hyperemia, epiphora, lid edema in female patient with COVID-19 infection.](image-url)

There was no significant difference between the group of patients with ocular manifestations and the group without ocular manifestation regarding age, gender, residence, body mass index, or comorbidities. However, smoking was significantly more prevalent among patients with ocular manifestations (P= 0.006) (Table 1).

None of COVID-19 related symptoms or signs were significantly associated with the presence of ocular manifestation. The clinical course of the disease was not significantly associated with the presence of ocular manifestations either. None with ocular manifestations in this study died, however, there was no significant difference between patients with or without ocular manifestations as regards the mortality rate (P=0.137) (Table 2). Patients with and those without ocular manifestation were comparable as regards the laboratory findings (Table 3).
Table 1. Characteristics of COVID-19 patients with and without ocular manifestations

| Character        | Ocular Manifestations | Total (n=228) | P Value |
|------------------|-----------------------|---------------|---------|
|                  | Yes (n=34)            | No (n=194)    |         |
| Age (y) Mean ±SD | 42.06 ± 16.41         | 42.18 ± 13.27 | 42.16 ± 13.91 | 0.122 |
| Gender           |                       |               |         |
| Male             | 20 (58.8%)            | 14 (41.2%)    | 127 (55.7%) | 101 (44.3%) | 0.713 |
| Female           | 14 (41.2%)            | 20 (58.8%)    | 139 (71.6%) | 55 (28.4%) | 0.133 |
| Residence        |                       |               |         |
| Rural            | 20 (58.8%)            | 14 (41.2%)    | 159 (69.7%) | 69 (30.3%) | 0.062 |
| Urban            |                       |               |         |
| Smoking          | 19 (55.9%)            | 61 (31.4%)    | 80 (35.1%) | 0.006 |
| Comorbidity      |                       |               |         |
| No               | 18 (52.9%)            | 149 (76.8%)   | 167 (73.2%) | 10 (4.4%) | 0.062 |
| Hepatic          | 2 (5.9%)              | 8 (4.1%)      | 6 (2.6%) | 0.713 |
| Renal            | 2 (5.9%)              | 4 (2.1%)      | 17 (8.8%) | 23 (10.1%) | 0.133 |
| HTN & Cardiac    |                       |               |         |
| Diabetes         | 6 (17.6%)             | 16 (8.2%)     | 22 (9.6%) | 0.062 |
| BMI              |                       |               |         |
| Normal           | 2 (5.9%)              | 10 (5.2%)     | 12 (5.3%) | 0.120 |
| Overweight       | 12 (35.3%)            | 106 (54.6%)   | 118 (51.8%) | 86 (37.7%) | 0.133 |
| Obese            | 3 (8.8%)              | 9 (4.6%)      | 12 (5.3%) | 0.062 |
| Morbid obesity   |                       |               |         |
| HTN: Hypertension, BMI: Body Mass Index.  

Table 2. COVID-19 related symptoms, signs, and clinical outcomes in patients with and without ocular manifestations.

| Manifestations | Ocular Manifestations | Total (n=228) | P Value |
|----------------|-----------------------|---------------|---------|
|                | Yes (n=34)            | No (n=194)    |         |
| Fever          | 14 (41.2%)            | 88 (45.4%)    | 102 (44.7%) | 80 (35.1%) | 0.982 |
| No             | 12 (35.3%)            | 68 (35.1%)    | 80 (35.1%) | 46 (20.2%) | 0.080 |
| Mild           | 8 (23.5%)             | 38 (19.6%)    | 45 (19.7%) | 0.952 |
| High           |                       |               |         |
| Headache       | 12 (35.3%)            | 72 (37.1%)    | 84 (36.8%) | 0.839 |
| Sore throat    | 7 (20.6%)             | 44 (22.7%)    | 51 (22.4%) | 0.787 |
| Cough          | 27 (79.4%)            | 150 (77.3%)   | 177 (77.6%) | 37 (16.2%) | 0.962 |
| No             | 5 (14.7%)             | 32 (16.5%)    | 37 (16.2%) | 0.962 |
| Mild           | 2 (5.9%)              | 12 (6.2%)     | 14 (6.1%) | 0.962 |
| Continuous     |                       |               |         |
| Dyspnea        | 12 (35.3%)            | 70 (36.1%)    | 82 (36%) | 0.990 |
| No             | 15 (44.4%)            | 86 (44.3%)    | 101 (44.3%) | 45 (19.7%) | 0.982 |
| Mild           | 7 (20.6%)             | 38 (19.6%)    | 45 (19.7%) | 0.982 |
| Continuous     |                       |               |         |
| Anorexia       | 11 (32.4%)            | 69 (35.6%)    | 80 (35.1%) | 0.717 |
| Anosmia        | 11 (32.4%)            | 67 (34.5%)    | 78 (34.2%) | 0.805 |
| Pallor         | 1 (2.9%)              | 9 (4.6%)      | 10 (4.4%) | 0.656 |
| Fatigue        | 19 (55.9%)            | 108 (55.7%)   | 127 (55.7%) | 0.982 |
| Vomiting       | 7 (20.6%)             | 42 (21.6%)    | 49 (21.5%) | 0.889 |
| Diarrhea       | 18 (52.9%)            | 108 (55.7%)   | 126 (55.3%) | 95 (41.7%) | 0.952 |
| No             | 15 (44.4%)            | 80 (41.2%)    | 85 (37.7%) | 95 (41.7%) | 0.952 |
| 3-6 times      | 1 (2.9%)              | 6 (3.1%)      | 7 (3.1%) | 0.952 |
| >6 times       | 6 (17.6%)             | 36 (18.6%)    | 42 (18.4%) | 0.90 |
| Abdominal pain |                       |               |         |
| Clinical course| 27 (79.4%)            | 114 (58.8%)   | 141 (61.8%) | 58 (25.4%) | 0.080 |
| Mild           | 5 (14.7%)             | 53 (27.3%)    | 58 (25.4%) | 0.080 |
| Moderate       | 2 (5.9%)              | 27 (13.9%)    | 29 (12.7%) | 0.080 |
Table 3. Laboratory findings in patients with and without ocular manifestations.

| Lab. Findings | Ocular Manifestations | Total (n=228) |
|---------------|-----------------------|--------------|
|               | Yes (n=34)            | No (n=194)   | P Value |
| Hb            | Mean ±SD              | Mean ±SD     |          |
|               | 13.12 ± 2.12          | 13.08 ± 2.07 | 13.09 ± 2.07 | 0.923 |
| Platelets     | 232.67 ± 84.29        | 225.78 ± 82.93 | 226.80 ± 82.98 | 0.625 |
| WBCs          | 5.80 ± 3.88           | 5.52 ± 3.20  | 5.56 ± 3.30 | 0.989 |
| Lymphocytes   | 36.58 ± 21.91         | 35.10 ± 20.78 | 35.32 ± 20.90 | 0.758 |
| Direct bilirubin | 0.27 ± 0.17        | 0.29 ± 0.18  | 0.28 ± 0.18 | 0.447 |
| Indirect bilirubin | 0.52 ± 0.17       | 0.51 ± 0.17  | 0.51 ± 0.17 | 0.767 |
| Albumin       | 4.07 ± 0.46           | 4.02 ± 0.50  | 4.03 ± 0.49 | 0.628 |
| ALT           | 29.71 ± 16.28         | 30.02 ± 16.09 | 29.97 ± 16.08 | 0.917 |
| AST           | 27.71 ± 9.92          | 28.43 ± 9.74  | 29.97 ± 16.08 | 0.681 |
| INR           | 1.06 ± 0.13           | 1.07 ± 0.13  | 1.07 ± 0.13 | 0.745 |
| D dimer       | 0.49 ± 0.46           | 0.50 ± 0.47  | 0.50 ± 0.47 | 0.975 |
| LDH           | 210.97 ± 144.32       | 207.55 ± 143.71 | 208.06 ± 143.49 | 0.868 |
| Ferritin      | 324.20 ± 564.87       | 331.80 ± 570.56 | 330.67 ± 568.48 | 0.076 |
| Creatinine    | 0.95 ± 0.24           | 0.94 ± 0.23  | 0.95 ± 0.23 | 0.097 |
| CRP           | 14.82 ± 25.54         | 12.22 ± 16.92 | 12.60 ± 18.42 | 0.757 |

Hb: Hemoglobin, WBC: White Blood Cells, ALT: Alanine Transaminase, AST: Aspartate Transaminase, INR: International Normalized Ratio, LDH: Lactate Dehydrogenase, CRP: C-Reactive Protein.

Patients with conjunctivitis were treated with topical antibiotics to prevent secondary bacterial infection, topical steroid, and tear substitutes. The viral conjunctivitis in all the affected patients resolved within 10 days with complete recovery of ocular symptoms and signs without any permanent ocular damage. The presence of ocular manifestations was not a significant predictor of the patients’ mortality. The percentage of oxygen saturation was the only significant predictor for the patients’ mortality (Table 4).

Table 4. Logistic regression of the effect of potential mortality predictor of the studied patients.

| Variables       | B     | P-Value | OR   | 95% CI  |
|-----------------|-------|---------|------|---------|
|                 |       |         | Lower| Upper   |
| Age             | 0.012 | 0.542   | 1.012| 0.974   | 1.052 |
| Gender          | -1.13 | 0.089   | 0.323| 0.088   | 1.190 |
| Smoking         | 0.967 | 0.084   | 2.650| 0.879   | 7.867 |
| ALT             | 0.00  | 0.980   | 1.00 | 0.967   | 1.035 |
| Albamnin        | 0.776 | 0.176   | 2.173| 0.706   | 6.685 |
| Creatinine      | -0.997| 0.432   | 0.369| 0.031   | 4.435 |
| Ferritin        | -0.001| 0.565   | 0.999| 0.998   | 1.001 |
| CRP             | -0.015| 0.554   | 0.985| 0.939   | 1.034 |
| O₂ sat.         | 3.490 | <0.001  | 32.79| 8.634   | 124.548 |

4. DISCUSSION

A very few articles have assessed the ophthalmological manifestation in patients with SARS-CoV-1 or SARS-CoV-2 infection. To our knowledge, none of these reports have evaluated the prognostic value of these findings. Our article aimed to evaluate the ocular finding of COVID-19 during the pandemic period in two big isolation hospitals in Egypt and if these ocular manifestations could help the physician to predict the course of the disease.
Our results showed that the incidence of ocular manifestation was 14.9% and all the ocular manifestation was in the form of conjunctivitis, which had been treated and resolved completely within 10 days in all patients without any permanent ocular damage. Conjunctivitis is presumed to be self-limited and can be managed with symptomatic care as weak steroid eye drops and lubricant. Ocular shedding of SARS-CoV-2 via tears is a distinct possibility of which ophthalmologists should be aware.

According to our findings, the presence of ocular manifestation tends to be associated with mild and moderate cases and with less aggressive course of the disease. Future research is needed to explain the presence of ocular manifestations, mainly in mild and moderate cases.

In a previous report, the incidence of ocular manifestation was found to be 0.8% (9/1099 patients) from 552 hospitals across 30 provinces in China, these ocular manifestations were described as conjunctival congestion [14].

A recent case series from Hubei province, China demonstrated the presence of ocular symptoms in 12 (31.6%) of 38 hospitalized patients with COVID-19. These ocular manifestations included conjunctival hyperemia (3 patients), chemosis (7 patients), epiphora (7 patients), or increased secretions (7 patients) [13]. In addition, Xia et al. [14] reported that out of 30 hospitalized patients with COVID-19, one patient had conjunctivitis.

Retinal changes are also thought to be linked with COVID-19 infection. Subclincial hyper reflective lesions at the level of ganglion cell layer and the inner plexiform layer are found in 12 adults examined using optical coherence tomography after systemic disease onset; cotton wool spots and hemorrhages were found on fundus examinations in 4 of these patients [15]. Inverriuzzy et al. found retinal hemorrhages (9.25%), cotton wool spots (7.4%), tortuous vessels (12.9%) and dilated veins (27.7%) in 54 patients with COVID-19 upon screening with fundus photography [16]. Lecler et al. showed abnormal MRI findings in the posterior pole of 9 patients with COVID-19 consisting of one or multiple hyper intense nodules in the macular region on FLAIR-weighted images [17]. These lesions were supposed to be either direct inflammatory infiltration of the retina or microangiopathic disease from viral infection.

Limitation of this study: the retrospective nature of the study and lack of posterior segment examination due to the infectious nature of the disease and the increase in the number of patients in the isolation hospital and the increased anxiety of the patients, which prevent the dilatation of pupil and careful examination of the retina and the use of further investigation as optical coherence tomography and fluorescein angiography. Despite above-mentioned limitation, we have described for the first time the ocular manifestation of COVID-19 in the Middle East and Africa, in an effort to inform ophthalmologists and others around the world about the ocular manifestations of COVID-19 and their role in the prediction of the course of the disease.

CONCLUSION

Ophthalmic manifestation is common in patients with COVID-19 and it occurs more frequently in patients with mild to moderate form of COVID-19, but it could not predict the patient’s mortality.

AUTHORS’ CONTRIBUTION

R.G., S.A, M.K, E.E, A.G, and D.E. collected the study data, wrote, revised and approved the manuscript. O.A., H.F., S.S, M.A., M.A., K.O, and D.E. performed the statistical analysis, collected the study data, wrote, revised and approved the manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The approval was obtained from the ethics committee of Tanta University, Faculty of Medicine, Egypt.

HUMAN AND ANIMAL RIGHTS

No animals were used in this research. All human research procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2013.

CONSENT FOR PUBLICATION

An informed consent was obtained from the all participants

STANDARDS OF REPORTING

STROBE guideline has been followed in this study

AVAILABILITY OF DATA AND MATERIALS

Not applicable

FUNDING

None.

CONFLICT OF INTEREST

Sherief Abd-Elsalam is the Editorial board member of The Open Biomarkers Journal.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients...
with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33. [http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]

[2] Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respiriology 2018; 23(2): 130-7. [http://dx.doi.org/10.1111/resp.13196] [PMID: 29052924]

[3] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origin and receptor binding. Lancet 2020; 395(10224): 565-74. [http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]

[4] Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: A multi-center randomized study. Arch Virol 2021; 166(3): 949-54. [http://dx.doi.org/10.1007/s00705-021-04095-9] [PMID: 33492523]

[5] Mohamed AA, Mohamed N, Mohamoud S, et al. SARS-CoV-2: The path of prevention and control. Infect Disord Drug Targets 2021; 21(3): 358-62. [http://dx.doi.org/10.2174/1871526520666200520112848] [PMID: 32433010]

[6] Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949. [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205250]

[7] Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APACOS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int 2020; 14(5): 690-700. [http://dx.doi.org/10.1111/hinf.13272] [PMID: 32623632]

[8] Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis 2020; 35: 101647. [http://dx.doi.org/10.1016/j.tmaid.2020.101647] [PMID: 32247927]

[9] Xie M, Chen Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 2020; 94: 119-24. [http://dx.doi.org/10.1016/j.ijid.2020.03.071] [PMID: 32247050]

[10] Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc 2020; 83(6): 534-6. [http://dx.doi.org/10.1097/JCMA.0000000000000318] [PMID: 32243270]

[11] Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med 2003; 349(25): 2431-41. [http://dx.doi.org/10.1056/NEJMoa032498] [PMID: 14681510]

[12] Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020; 138(5): 575-8. [http://dx.doi.org/10.1001/jamaophthalmol.2020.1291] [PMID: 32332433]

[13] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20. [http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]

[14] Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol 2020; 92(6): 589-94. [http://dx.doi.org/10.1002/jmv.25725] [PMID: 32100876]

[15] Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R Jr. Retinal findings in patients with COVID-19. Lancet 2020; 395(10237): 1610. [http://dx.doi.org/10.1016/S0140-6736(20)31014-X] [PMID: 32405105]

[16] Invernizzi A, Torre A, Parrulli S, et al. Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. EClinicalMedicine 2020; 27: 100550. [http://dx.doi.org/10.1016/j.eclinm.2020.100550] [PMID: 32984785]

[17] Lecler A, Cotton F, Lersy F, Kremer S, Héran F. Ocular MRI findings in patients with severe COVID-19: A retrospective multicenter observational study. Radiology 2021; 299(2): E226-9. [http://dx.doi.org/10.1148/radiol.2021204394] [PMID: 33591889]